Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Immunic, Inc.NASDAQ: IMUX
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin not reported for Q1 FY2026
Sources:Income StatementText generated from reported figures; not investment advice.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How IMUX compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 14.5% | +137.1 pp | +100715.3 pp | |
| LTM Mar 2026 | -1360.6% | +1613.5 pp | -767.6 pp | |
CBUSCibus, Inc. | LTM Mar 2026 | -2366.3% | +3418.5 pp | +7266.3 pp |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding IMUX) | -1360.6% | +1613.5 pp | +7266.3 pp | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| Weighted Avg Shares | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
| Weighted Avg Shares (Diluted) | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.